Business Description
United Therapeutics Corp
NAICS : 325412
SIC : 2836
ISIN : US91307C1027
Share Class Description:
UTHR: Ordinary SharesTotal Employee Number:
1,400Compare
Compare
Traded in other countries / regions
UTHR.USAUTH.GermanyU2TH34.Brazil Index Membership
Russell 1000Russell 3000MSCI World Index IPO Date
1999-06-17Description
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.89 | |||||
Interest Coverage | 116.95 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 19.02 | |||||
Beneish M-Score | -3.07 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 18.5 | |||||
3-Year EBITDA Growth Rate | 21.2 | |||||
3-Year EPS without NRI Growth Rate | 23.4 | |||||
3-Year FCF Growth Rate | 16.5 | |||||
3-Year Book Growth Rate | 16 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 8.8 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 7.87 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 40.83 | |||||
9-Day RSI | 42.34 | |||||
14-Day RSI | 42.74 | |||||
3-1 Month Momentum % | -7.8 | |||||
6-1 Month Momentum % | -5.84 | |||||
12-1 Month Momentum % | 25.96 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.73 | |||||
Quick Ratio | 5.41 | |||||
Cash Ratio | 4.38 | |||||
Days Inventory | 150.42 | |||||
Days Sales Outstanding | 38.17 | |||||
Days Payable | 5.93 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 1.8 | |||||
Shareholder Yield % | 11.98 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 86.14 | |||||
Operating Margin % | 44.49 | |||||
Net Margin % | 41.56 | |||||
EBITDA Margin % | 53.15 | |||||
FCF Margin % | 34.54 | |||||
OCF Margin % | 53.31 | |||||
ROE % | 19.77 | |||||
ROA % | 17.68 | |||||
ROIC % | 27.67 | |||||
3-Year ROIIC % | 28.88 | |||||
ROC (Joel Greenblatt) % | 84.27 | |||||
ROCE % | 23.15 | |||||
Years of Profitability over Past 10-Year | 9 | |||||
Moat Score | 7 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 17.79 | |||||
Forward PE Ratio | 16.74 | |||||
PE Ratio without NRI | 19.06 | |||||
Shiller PE Ratio | 29.34 | |||||
Price-to-Owner-Earnings | 20.51 | |||||
PEG Ratio | 0.83 | |||||
PS Ratio | 7.31 | |||||
PB Ratio | 3.32 | |||||
Price-to-Tangible-Book | 3.38 | |||||
Price-to-Free-Cash-Flow | 21.39 | |||||
Price-to-Operating-Cash-Flow | 13.82 | |||||
EV-to-EBIT | 11.46 | |||||
EV-to-Forward-EBIT | 11.88 | |||||
EV-to-EBITDA | 10.84 | |||||
EV-to-Forward-EBITDA | 11.26 | |||||
EV-to-Revenue | 5.76 | |||||
EV-to-Forward-Revenue | 5.22 | |||||
EV-to-FCF | 16.68 | |||||
Price-to-GF-Value | 1.16 | |||||
Price-to-Projected-FCF | 1.33 | |||||
Price-to-Median-PS-Value | 1.5 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.75 | |||||
Price-to-Graham-Number | 1.63 | |||||
| Price-to-Net-Current-Asset-Value | 7.97 | |||||
| Price-to-Net-Cash | 11.52 | |||||
Earnings Yield (Greenblatt) % | 8.73 | |||||
FCF Yield % | 5.11 | |||||
Forward Rate of Return (Yacktman) % | 23.57 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:UTHR
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
United Therapeutics Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 3,154.5 | ||
| EPS (TTM) ($) | 27.958 | ||
| Beta | 0.2107 | ||
| 3-Year Sharpe Ratio | 0.86 | ||
| 3-Year Sortino Ratio | 2.34 | ||
| Volatility % | 42.59 | ||
| 14-Day RSI | 42.74 | ||
| 14-Day ATR ($) | 13.446724 | ||
| 20-Day SMA ($) | 506.1545 | ||
| 12-1 Month Momentum % | 25.96 | ||
| 52-Week Range ($) | 402.5 - 609.35 | ||
| Shares Outstanding (Mil) | 42.89 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
United Therapeutics Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
United Therapeutics Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-25 09:00 | In 161 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-25 06:30 | In 161 days | ||
| Annual report for 2026 | 2027-02-25 | In 160 days | ||
| Third quarter earnings conference call for 2026 | 2026-10-29 09:00 | In 42 days | ||
| Third quarter earnings results for 2026 | 2026-10-29 | In 41 days | ||
| Bernstein 3rd Annual Healthcare Forum | 2026-09-23 13:20 | In 6 days | ||
| Morgan Stanley 24th Annual Global Healthcare Conference | 2026-09-14 16:50 | 497.11 (-1.68%) | ||
| Cantor Global Healthcare Conference | 2026-09-09 14:10 | 497.97 (+0.65%) | ||
| Wells Fargo 21st Annual Healthcare Conference | 2026-09-08 11:00 | 487.61 (+0.68%) | ||
| Second quarter earnings conference call for 2026 | 2026-08-05 09:00 | 518.68 (+0.16%) |
Show
Entries
United Therapeutics Corp Frequently Asked Questions
What is United Therapeutics Corp(UTHR)'s stock price today?
The current price of UTHR is $497.27. The 52 week high of UTHR is $609.35 and 52 week low is $402.50.
When is next earnings date of United Therapeutics Corp(UTHR)?
The next earnings date of United Therapeutics Corp(UTHR) is 2026-10-29 Est..
Does United Therapeutics Corp(UTHR) pay dividends? If so, how much?
United Therapeutics Corp(UTHR) does not pay dividend.
Guru Commentaries on NAS:UTHR
Arquitos Capital Management
Bearish
2026 Q2
What the manager wrote
The ongoing legal battle between Liquidia and United Therapeutics over the '327 patent is a significant concern. I believe the most likely outcome is that United Therapeutics' patent will be ruled invalid, which would favor Liquidia. However, if the patent is upheld and Liquidia is found to have infringed, it could lead to a royalty scenario that may not be favorable for United Therapeutics. The uncertainty surrounding the patent decision and its implications for United Therapeutics' market position raises red flags about its future performance.
Polaris Global Equity
Bullish
2026 Q1
1Q2026global
Polaris Wealth Advisory Group, LLC
· 169 holdings
What the manager wrote
United Therapeutics Corp. rebounded at the very end of March after announcing that its TETON-1 pivotal study of nebulized Tyvaso met its primary endpoint in idiopathic pulmonary fibrosis. This positive outcome is expected to enhance the company's growth trajectory and market position in the healthcare sector, particularly in treating pulmonary diseases. The strong performance of United Therapeutics Corp. reflects its potential for continued success and value creation in the biotechnology space.
Press Release
Headlines
See More- 1
Sep 08, 2026
United Therapeutics enters $477.6M accelerated share repurchase
Seeking Alpha • 6:50am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers